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ABSTRACT
Objectives: To assess the relation between the
number of clinical trials conducted and respective new
drug approvals in India and South Africa.
Design: Construction and analysis of a comprehensive
database of completed randomised controlled clinical
trials based on clinicaltrials.gov from 1 January 2005
to 31 December 2010 and drug approval data from
2006 until 2013 for India and South Africa.
Setting: USA, the EU, India and South Africa.
Main outcome measures: Percentage of completed
randomised clinical trials for an Investigational
Medicinal Product (IMP) leading to new drug approval
in India and South Africa.
Results: A total of 622 eligible randomised controlled
trials were identified as per search criteria for India and
South Africa. Clustering them for the same sponsor
and the same Investigational New Drug (IND) resulted
in 453 eligible trials, that is, 224 for India and 229 for
South Africa. The distribution of the market application
approvals between the EU/USA as well as India and
South Africa revealed that out of clinical trials with the
participation of test centres in India and/or South
Africa, 39.6% (India) clinical trials and 60.1% (South
Africa) clinical trials led to market authorisation in the
EU/USA without a New Drug Application (NDA)
approval in India or South Africa.
Conclusions: Despite an increase in clinical trial
activities, there is a clear gap between the number of
trials conducted and market availability of these new
drugs in India and South Africa. Drug regulatory
authorities, investigators, institutional review boards
and patient groups should direct their efforts to
ensuring availability of new drugs in the market that
have been tested and researched on their population.
INTRODUCTION
The drugs we use to treat any condition—
from an innocuous cough to a life-
threatening cancer—are the outcome of
painstaking human clinical trials. These trials
are the only way to credibly determine the
safety and efﬁcacy of drugs. Without trials,
there is no way pharmaceutical research can
advance to improve disease management
and the very quality of life. Clinical trials are
considered as a gold standard in the ﬁeld of
evidence-based medicine.1 In recent years,
there has been a clear shift in clinical trial
sites from core developed countries like the
USA and European countries to developing
countries like India, China and South
American countries.2 This shift is related to
challenges and opportunities like costs of
trials, recruitment issues and regulatory chal-
lenges in developed versus developing coun-
tries.3–5 Since the early 1990s, the growth in
the number of people participating in and
required for pharmaceutical clinical trials
has been massive. The number of clinical
trial investigators conducting multinational
clinical trials (trials conducted in more than
one country with the same protocol) in low-
income settings increased 16-fold in the past
decade.3 Many of these new trials are being
performed in geographical areas of political
and economic instability and unprecedented
healthcare crises and where subjects are
readily accessible. Drug companies’ apparent
ease of accessibility to such areas has raised
questions about the unequal social contexts
in which research is being performed and
about how conditions of inequality are at
present facilitating a global proliferation of
pharmaceutical drug trials. This increase
brings with it social, legal and ethical impli-
cations, and among them are the major issue
of how the beneﬁts of this research are
shared.2 6 7 Our university contact partners
from developing countries—India and South
Africa—had shown interest in this research
question as randomised controlled trials
Strengths and limitations of this study
▪ We only selected clinical trials conducted from
1st of January to 31st December 2010 for this
study.
▪ http://www.clinicaltrials.gov was the only source
for selection of clinical trials this study.
▪ We might have missed other websites as source
to identify registered clinical trials.
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conducted in India and South Africa have not been
comprehensively assessed, and there is no effort to
determine whether this research has led to the availabil-
ity of new drugs to the local population. We also feel this
research question will beneﬁt the clinical research envir-
onment in the respective countries. We therefore con-
structed a comprehensive database of randomised
controlled trials in India and South Africa from 2005 to
2010 and evaluated whether this research has resulted in
market approvals of new drugs.
METHODS
Eligibility criteria
We screened all multinational randomised controlled
trials from http://www.clinicaltrials.gov conducted in
the period from 1 January 2005 to 31 December 2010.
Multinational trials that had trial sites in India and
South Africa were selected for this study.
Identification of trials and new drug approvals
We searched the US trials registry of the National
Institutes of Health, ClinicalTrials.gov, the main global
trial registration site to identify clinical trials conducted
by global sponsors in preselected developing countries,
India and South Africa. We only selected the trials which
were interventional, phase II and III, funded by industry,
registered, conducted and completed between 1 January
2005 and 31 December 2010, as some of the trials might
be registered or conducted but may not be completed
in the predecided time frame for this research question.
After clinical trial completion, the sponsor has to submit
the clinical study report within 12 months to the regula-
tory authorities. On this basis, we decided that
14 months was an adequate period for the sponsor to ﬁle
a New Drug Application (NDA) in the relevant country.
Therefore, we excluded the clinical trials having update
information later than 14 month after completion date.
We searched http://www.fda.gov US Food and Drug
Administration, http://www.ema.europa.eu European
Medicines Agency, http://www.cdsco.nic.in Central
Drug Standard Control Organization, India (CDSCO)
and http://www.mccza.com Medicines Control Council
(MCC), South Africa along with South African Medicine
Price Registry http://www.mpr.gov.za for new drug
approval in the USA, the EU, India and South Africa,
respectively, for the time period from 2006 until 2013.
Database
From each trial, we extracted the following information:
title of the trial, sponsor, indication and IMP
(Investigational Medicinal Product). From the new
product approval database, we extracted the new
product approval date. We reviewed the selected sets of
trials for a duplicate check on the sponsor, IMP and
indication to avoid miscounting the total number of
trials potentially being included in the New Drug
Approval list. Figure 1 gives the details of generation of
data. Search was repeated by us to validate the correct-
ness of data.
Analysis
Data analysis was done on the following determined
data sets by the following criteria: not approved in any
of the countries/regions; approved in the EU and/or
the USA, but not in India and South Africa, respectively;
approved in India/South Africa, respectively, and in
either the EU and/or the USA.
RESULTS
Figure 1 illustrates the initial generation of data and its
subsequent handling for analysis. We screened 1175
trials from http://www.clinicaltrials.gov registered in the
period from 1 January 2005 to 31 December 2010. Out
of 1175 trials, there were 596 and 579 trials for India
and South Africa, respectively. Trials with update infor-
mation later than 14-month after the completion date
were eliminated, which resulted in 320 and 302 trials for
India and South Africa, respectively. Further clustering
clinical trials with the same sponsor and same IND
resulted in 224 and 229 clinical trials for India and
South Africa, respectively. This formed the basis for our
Figure 1 Clinical trials and NDA approvals in India and
South Africa. NDA, New Drug Application.
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analysis. These clinical trials were screened at the Indian
regulatory site (http://www.cdsco.nic.in), South African
regulatory sites (http://www.mccza.com and http://
www.mpr.gov.za), European Medicines Agency site
(http://www.ema.europa.eu) and USFDA site (http://
www.fda.gov) to determine the new drug approval status
in respective countries.
Figure 2 shows the percentage of clinical trials leading
to market approval. 59.4% (India) and 39.8% (South
Africa) of the multinational clinical trials did not result
in NDA approval anywhere – not in the respective
country (India/South Africa) or the EU/USA. It was
seen that only 24.5% and 24% clinical trials led to mar-
keting approval in India and South Africa, respectively.
It was seen that in 16.1% approval was only available in
the EU and/or the USA without parallel approval in
India. In case of South Africa, this number was strikingly
high, that is, 36.2% trials led to approval in the EU and/
or the USA without parallel approval in South Africa.
Inequalities were more evident when we focused on
the distribution of marketing approval between the EU/
USA and India/South Africa as seen in ﬁgure 3. In 39.6%
and 60.1% trials, respectively, for India and South Africa,
marketing approval was only received in the EU/USA
without approval in India and South Africa, respectively.
Table 1 shows the % of clinical trials and % cause spe-
ciﬁc mortality as per the WHO report8 for India and
South Africa. There were a large number of clinical
trials for neuropsychiatric conditions (20%), diabetes
(19%) and cardiovascular diseases (16%) conducted in
India. Diabetes and cardiovascular diseases are listed
in the WHO Report as relevant causes for mortality in
India with a subsequent country programme to address
those diseases.8 For clinical trials conducted in South
Africa, neuropsychiatric conditions (22%) and various
types of malignancies (14.5%), followed by cardiovascu-
lar diseases (12.0%), were the main indications.
DISCUSSION
We identiﬁed clinical trials conducted from 1 January
2005 to 31 December 2010 and registered on http://
www.clinicaltrials.gov. Our results reveal that there is a
mismatch between the percentage of clinical trials con-
ducted and NDAs in India and South Africa. Globally, a
large number of multinational clinical trials (59.4% in
India and 39.8% in South Africa) did not result in NDA
approval anywhere, that is, in the respective country—
India/South Africa or the EU/USA. This is alarming
and highlights the problem with clinical success rate
Figure 2 Percentage of clinical trials leading to market approval.
Figure 3 Distribution of
marketing approval between the
EU/USA and India/South Africa.
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(movement of drug from clinical trials to the market).9
This is associated with many factors like trial costs, regu-
latory framework, trial complexity and patient recruit-
ment issues. Against this background, emerging
economies have shown the potential to become global
players in the ﬁeld of clinical research.
After focusing only on the percentage of clinical trials
resulting in an NDA, it was clear that for 39.6% and
60.1% trials, respectively, for India and South Africa,
marketing approval was only received in the EU/USA
without approval in India and South Africa. As regards
participation in the eventual beneﬁts, the Declaration of
Helsinki offers clear guidance, especially for research
conducted in the developing countries.10 The year 2000
version of the Declaration of Helsinki states categorically
that at the end of any research study, every subject
entered in the project should be assured of the best
proven prophylactic, diagnostic and therapeutic
methods identiﬁed by that study.10 The World Medical
Assembly emphasises that medical research is only justi-
ﬁed if there is a reasonable likelihood that the popula-
tions in which the research is carried out stand to
beneﬁt from the results of the research.10 The Indian
drug regulatory authorities ask sponsors to conﬁrm that
they will market the drug after conducting the trial on
the Indian population.11 However, the result of our
study clearly shows that this regulation is not followed by
sponsors even after they make a commitment on paper
with the regulatory authorities of India.
Also, it is very important to have a balance between
the research areas and the present need of the respect-
ive countries.4 12 Our results show the imbalance
between the focused research areas and the disease
prevalence of India and South Africa. Similar results
have also been reported by Glickman EW that global
players are not focusing their research on the priorities
of the developing countries.2 A comparison between the
cause speciﬁc mortality of India and South Africa and
the indications of clinical trials conducted revealed only
a partial match. There were no clinical trials in the area
of maternal and perinatal conditions, nutritional disor-
ders which are the main causes of mortality in India. We
would also like to focus on the high number of trials
conducted in the areas of neoplasms, neuropsychiatry,
musculoskeletal diseases and genitourinary diseases
which might not be relevant to the local population in
India. For South Africa, the WHO report8 conﬁrms car-
diovascular diseases and neoplasms as critical areas in
healthcare. However, infectious diseases and, in particu-
lar, HIV form by far the area associated with the highest
medical need, which are a far less explored indication
for clinical trials conducted in South Africa. Even for
South Africa there were a high number of clinical trials
in the area of neuropsychiatry, musculoskeletal diseases,
diabetes and genitourinary diseases which might not be
relevant as per the WHO cause speciﬁc mortality data to
the local population. This highlights the need to refocus
on the issue of vulnerability of emerging economies’
patient participation in the clinical trial in spite of dis-
cussions over the past decade.4 13 14
Implications for Ethics Committees and investigators
The National Bioethics Advisory Commission (NBAC)14
in its report recommends that researchers should,
before initiation of a research study, endeavour to secure
access for all participants to effective treatment after the
trial and that the lack of any such arrangements should
be justiﬁed to a research ethics committee (REC). The
report also recommends that researchers should indicate
in their proposals how they intend to make the interven-
tion available to participants after the trial if the inter-
vention is proven successful. There is a need to ensure
that developing countries are not used as sites for
research that is not of relevance to them and thus
protect the vulnerable population.4 The Council for
International Organizations of the Medical Sciences
Guidelines speciﬁcally state that all research that is con-
ducted in developing countries and sponsored by devel-
oped countries should be of relevance to the developing
countries. The relevance of the study to the country is a
sure way of ensuring that countries stand to beneﬁt once
their citizens participate as subjects in clinical research.
In the words of Lang and Siribaddana,4 “the globalisa-
tion of trials should not be about running inexpensive
Table 1 Percentage of clinical trials and % cause specific mortality for India and South Africa
India South Africa
Diseases Clinical trials %
Cause specific
mortality % Clinical trials %
Cause specific
mortality %
Musculoskeletal diseases 4 1.7 5 1
Neoplasm 13 3.5 14.5 3.2
Neuropsychiatric conditions 20 11.6 22 5.9
Cardiovascular diseases 16 12.6 12 7.7
Diabetes 19 11.0 15.7 1.8
Eye diseases 3 5.4 1.4 3.7
Digestive diseases 3 3 8.7 2
Infectious and parasitic diseases 13 17 9.1 48
Genitourinary diseases 5 1.1 4.5 1
Respiratory diseases 4 4.5 7.1 3
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trial sites to beneﬁt distant people, but should focus on
bringing research to populations who have previously
been under-represented in clinical trials and enabling
these same communities the beneﬁts from new drugs.”
Research Ethics Committees, being the gatekeepers
when it comes to health research, have to play an
important role of ensuring that the communities and
individuals are not exploited in research.12 More often,
it is very difﬁcult for a community to voice its concerns
due to various reasons including lack of appropriate
structures for communication. The ethics committees
can therefore serve as the voice of the voiceless commu-
nities and individuals in developing countries. The
developing countries and institutions need to come to
the negotiating table with sponsors since they have a
very useful resource in research—human beings who are
willing to participate in research. The beneﬁt sharing
ensures that the disadvantaged at least beneﬁt in some
way from an activity in which they have participated.
Implications for regulators
The pace of clinical research in developing countries is
accelerating in India and South Africa. Both these coun-
tries are not in a stage to support independent clinical
research like western developed countries. They need to
be a part of international clinical trials, but this should be
without compromising ethics and research beneﬁts
sharing. Regulatory authorities from India and South
Africa should formulate a regulation making it compul-
sory to market the new drugs at affordable prices in India
and South Africa after conducting clinical trials on the
local population. It is very important that clinical
research should focus on the most relevant disease of
these countries. There should be a provision to blacklist
or ﬁne the sponsor if they do not market the new drugs
in India or South Africa and market only in the EU/USA.
CONCLUSION
In this paper, we take the view that clinical research is
important for developing countries as it offers beneﬁts
in terms of knowledge, patient care and business.
Sponsors should not exploit the local population for
research without offering the beneﬁts of research by
making the new drug available in markets of developing
countries. Sponsors and investigators should take reason-
able efforts, plan before study initiation and discuss with
beneﬁts and risk of study with local communities.
Clinical research stands on the basic premise of enhan-
cing the present scientiﬁc knowledge and, if ethically
designed and conducted, it is the most scientiﬁc path to
invent new treatment modalities. Therefore, the beneﬁts
of this ethical research should be extended post trial not
only to study subjects but to the entire host community.
In general, the goal of clinical research is to support
the drug development and availability of new medicines
while ensuring that research is always balanced to the
local need of the country. There is a need not only to
have stringent regulations, but also to monitor its
follow-up. We feel that institutional review boards, inves-
tigators and patient groups, along with regulatory
authorities, have a clear role in ensuring market avail-
ability of drugs after research and thus bridging the gap
between the developing and developed nations.
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